In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oxford Immunotec Global PLC

http://www.oxfordimmunotec.com/

Latest From Oxford Immunotec Global PLC

BIORCHESTRA On Overcoming Challenges For miRNA Therapeutics In Neurodegeneration

After being selected as an awardee of J&J’s Innovation QuickFire Challenge On Neuroscience in June, Korean bioventure BIORCHESTRA has been attracting attention from the global neuroscience community. CEO Branden Ryu talks to Scrip what makes its technology unique and how it aims to meet major unmet needs in RNA therapeutics and neurodegenerative disorders.

South Korea Neurology

UK Steps Up Search For Vaccines Against ‘Variants Of Concern’

As the World Health Organization brands the Indian virus a “variant of concern,” the UK is planning to use a lab-grown virus variant in challenge trials of current and new vaccines, and is also investing in new variant vaccine testing facilities. A new study will use Oxford Immunotec’s T cell test to monitor people’s immunological response to infection or vaccination.

United Kingdom Europe

Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions

During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.

M & A Deals

Coronavirus Notebook: EU To Buy 30 Million Doses Of Valneva Vaccine, Russia To Issue Compulsory License For Remdesivir

The European Medicines Agency says hacked COVID-19 vaccine data has been leaked online, and Australia’s chief medical officer defends the Oxford/AstraZeneca vaccine against scientists’ claim that it is not effective enough.

Europe Coronavirus COVID-19
See All

Company Information

  • Industry
  • Laboratory Testing Services
  • Pharmaceuticals
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Cytology
  • Other Names / Subsidiaries
    • Immunetics, Inc.
    • Oxford Immunotec, Inc.
    • Oxford Immunotec Ltd.
UsernamePublicRestriction

Register